What is the lymphoma of the primary central nervous system?

The primary lymphoma of the central nervous system is a rare cancer tumor that develops from cells in the central nervous system, which consists of brain, eyes and spinal cord. Cancer can also be described as primary Lymphom CNS or PCNSL. The primary tumor is the one that originated in the place where it grows, while the secondary tumor is one that has spread from anywhere, so it is assumed that the primary CNS lymphoma is developed from nerve cells in the central nervous system. It is not entirely understood how this happens because lymphomas normally develop from the lymphatic tissue that is part of the immune system and is not found in the central nervous system. Although the lymphoma of the primary central nervous system is rare, it happens more often in people who have immunosuppression where the immune system is weak, because of diseases such as AIDS or after organs. This may be caused by blocking the flow of the fluid that surrounds the brain or directly rising tumor mass. Increasing pressureIt can lead to visual problems, headaches and vomiting. Other symptoms caused by a tumor may include growing confusion and seizures. If certain areas of the brain are affected by lymphoma, balance and coordination problems may develop and can occasionally become weak with one side of the body.

The primary lymphoma of the central nervous system is known as high-quality lymphoma non-hodgkins, which means that it tends to grow rapidly and is more likely to spread than a low degree tumor. Treatment of primary intracranial tumor varies according to the location and size of the lymphoma and whether it has already expanded. A person who is otherwise healthy may require different treatment from someone who is immunosupressed. There is no best treatment option, but chemotherapy can be used, sometimes in combination with radiotherapy and steroids, the pressure inside the skull can reduce swelling and tumor size.

view pRO someone with primary central nervous lymphoma varies according to an individual and the type of treatment accepted, but long -term survival is unusual. In general, there is a 50 % chance of survival for more than two years. Younger patients who have better overall health have a more positive prognosis.